

# Milan Lukas

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3096018/milan-lukas-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98 papers	8,912 citations	37 h-index	94 g-index
144 ext. papers	10,147 ext. citations	4.4 avg, IF	5.25 L-index

#	Paper	IF	Citations
98	A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.. <i>Scandinavian Journal of Gastroenterology</i> , <b>2022</b> , 1-11 <sup>2,4</sup>		
97	Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> ,	4.5	6
96	Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	2
95	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. <i>Gastroenterology</i> , <b>2021</b> , 160, 1452-1460.e21	13.3	15
94	Novel porcine model of Crohn's disease anastomotic stricture suitable for evaluation and training of advanced endoscopic techniques. <i>Gastrointestinal Endoscopy</i> , <b>2021</b> , 93, 250-256	5.2	4
93	Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211032790	4.7	4
92	Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 1066-1073	1.5	7
91	Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases. <i>Intestinal Research</i> , <b>2020</b> , 18, 34-44	4.1	6
90	Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 915-919	1.5	18
89	Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 789-796	4.5	34
88	Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 1181-1187	5.4	5
87	Infliximab Biosimilar (Remsuma) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre. <i>Digestive Diseases</i> , <b>2017</b> , 35, 91-100	3.2	36
86	Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 885-890	4.1	20
85	Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 282-291	6.1	28
84	Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm. <i>Gastroenterology</i> , <b>2017</b> , 152, S155	13.3	12
83	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <i>Lancet, The</i> , <b>2017</b> , 390, 2779-2789	40	403
82	Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 97-106	4.5	110

81	Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn's disease and ulcerative colitis. <i>Journal of Breath Research</i> , <b>2017</b> , 12, 016002	3.1	27
80	Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 196-202	2.4	40
79	Biosimilars: A Multidisciplinary Perspective. <i>Clinical Therapeutics</i> , <b>2016</b> , 38, 1238-49	3.5	24
78	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , <b>2016</b> , 150, 1568-1578	13.3	171
77	Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease. <i>Biologicals</i> , <b>2016</b> , 44, 33-6	1.8	30
76	Biosimilar infliximab in anti-TNF-naïve IBD patients 1-year clinical follow-up. <i>Gastroenterologie A Hepatologie</i> , <b>2016</b> , 70, 514-522	1.4	2
75	Sa1957 Switching of Patients With Inflammatory Bowel Disease From Original Infliximab (Remicade®) to Biosimilar Infliximab (Remsimab) Is Effective and Safe. <i>Gastroenterology</i> , <b>2016</b> , 150, S416	13.3	5
74	515 Biosimilar Infliximab Is Effective and Safe in Inflammatory Bowel Disease Patients Naïve to Anti-TNF Therapy: A Tertiary Center Experience. <i>Gastroenterology</i> , <b>2016</b> , 150, S106	13.3	2
73	Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , <b>2016</b> , 10, 1294-1302	1.5	45
72	Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , <b>2016</b> , 10, 1273-1278	1.5	56
71	Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. <i>Gut</i> , <b>2015</b> , 64, 243-9	19.2	113
70	Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequences. <i>Dermatologic Therapy</i> , <b>2014</b> , 27, 131-4	2.2	5
69	Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 743-4	6.1	6
68	Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 495-501	4.5	62
67	The relationship between serum bilirubin and Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 481-7	4.5	35
66	Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 970-80	1.5	29
65	OP011 Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe ulcerative colitis: A phase 2 randomized placebo-controlled study. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, S7-S8	1.5	5
64	Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases. <i>Autoimmunity Highlights</i> , <b>2013</b> , 4, 27-32	3.7	2

63	Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. <i>Journal of Crohnts and Colitis</i> , <b>2013</b> , 7, 736-43	1.5	179
62	Vedolizumab as induction and maintenance therapy for Crohn's disease. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 711-21	59.2	1328
61	The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 1109-18	6.1	16
60	Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. <i>Gut</i> , <b>2013</b> , 62, 1556-65	19.2	184
59	When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel. <i>Journal of Crohnts and Colitis</i> , <b>2013</b> , 7, 820-6	1.5	43
58	Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF- $\alpha$ therapy during pregnancy: three-center study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 951-8	2.4	51
57	Quantification of pentane in exhaled breath, a potential biomarker of bowel disease, using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , <b>2013</b> , 27, 1983-92	2.2	54
56	Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 590-8	4.5	15
55	Endoscopic Balloon Dilatation of Anastomotic Strictures in Patients With Crohn's Disease: Effect of Immediate Endoscopic Success and Biological Therapy. <i>Gastroenterology</i> , <b>2011</b> , 140, S-281	13.3	2
54	Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. <i>Gastroenterology</i> , <b>2011</b> , 140, 425-434.e1; quiz e13-4	13.3	76
53	3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. <i>Journal of Crohnts and Colitis</i> , <b>2011</b> , 5, 129-38	1.5	50
52	The clinical implication of drug dependency in children and adults with inflammatory bowel disease: a review. <i>Journal of Crohnts and Colitis</i> , <b>2011</b> , 5, 81-90	1.5	6
51	Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 313-22	6.1	51
50	Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis. <i>BMC Gastroenterology</i> , <b>2011</b> , 11, 47	3	13
49	Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 1322-7	4.5	85
48	Two independent genetic factors responsible for the associations of the IBD5 locus with Crohn's disease in the Czech population. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 1523-9	4.5	7
47	Impaired deoxyribonuclease I activity in patients with inflammatory bowel diseases. <i>Autoimmune Diseases</i> , <b>2011</b> , 2011, 945861	2.9	25
46	Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. <i>Gut</i> , <b>2010</b> , 59, 752-9	19.2	133

45	Inflammatory bowel disease as a risk factor for colorectal cancer. <i>Digestive Diseases</i> , <b>2010</b> , 28, 619-24	3.2	67
44	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. <i>Journal of Crohns and Colitis</i> , <b>2010</b> , 4, 63-101	1.5	578
43	Anti-inflammatory effect of biological treatment in patients with inflammatory bowel diseases: calprotectin and IL-6 changes do not correspond to sRAGE changes. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2010</b> , 70, 294-9	2	12
42	Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 144-50	2.2	18
41	Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 1196-203	2.2	12
40	Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , <b>2010</b> , 16, 1180-6	4.5	76
39	The CTLA4 variants may interact with the IL23R- and NOD2-conferred risk in development of Crohn's disease. <i>BMC Medical Genetics</i> , <b>2010</b> , 11, 91	2.1	13
38	Role of HSP-90 for increased nNOS-mediated vasodilation in mesenteric arteries in portal hypertension. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 1837-44	5.6	8
37	NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 5233-40	5.6	15
36	Association of IL23R p.381Gln and ATG16L1 p.197Ala with Crohn disease in the Czech population. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2009</b> , 49, 405-10	2.8	11
35	Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD?. <i>Inflammation Research</i> , <b>2009</b> , 58, 503-12	7.2	31
34	Infliximab dependency in children with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 29, 792-9	6.1	19
33	Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. <i>Gastroenterology</i> , <b>2009</b> , 137, 1250-60; quiz 1520	13.3	377
32	Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. <i>Gastroenterology</i> , <b>2009</b> , 137, 1934-43.e1-3	13.3	120
31	A patient with duodenal stenosis in Crohn's disease: endoscopic and drug treatment may be successful <b>2009</b> , 109-115		
30	Variants of CARD15, TNFA and PTPN22 and susceptibility to Crohn's disease in the Czech population: high frequency of the CARD15 1007fs. <i>Tissue Antigens</i> , <b>2008</b> , 71, 538-47		18
29	IBD patients need in health quality of care ECCO consensus. <i>Journal of Crohns and Colitis</i> , <b>2008</b> , 2, 181-81.5	1.5	44
28	CYP7A1 promoter polymorphism -203A>C affects bile salt synthesis rate in patients after ileal resection. <i>Journal of Lipid Research</i> , <b>2008</b> , 49, 2664-7	6.3	13

27	Improved HPLC analysis of serum 7alpha-hydroxycholest-4-en-3-one, a marker of bile acid malabsorption. <i>Clinical Chemistry</i> , <b>2008</b> , 54, 1087-8	5.5	15
26	Polymorphisms of the TPMT gene in the Czech healthy population and patients with inflammatory bowel disease. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2008</b> , 27, 835-8	1.4	5
25	Fatal myelotoxicity after azathioprine treatment. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2008</b> , 27, 661-5	1.4	13
24	What is the time for surgery in severe Crohn's disease?. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, S271-S272	4.5	2
23	What is the time for surgery in severe Crohn's disease?. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14 Suppl 2, S271-2	4.5	2
22	Non-adherence to treatment in inflammatory bowel disease in Czech Republic. <i>Journal of Crohns and Colitis</i> , <b>2007</b> , 1, 77-81	1.5	18
21	Nonadherence in inflammatory bowel disease: results of factor analysis. <i>Inflammatory Bowel Diseases</i> , <b>2007</b> , 13, 1244-9	4.5	106
20	A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. <i>Wiener Klinische Wochenschrift</i> , <b>2007</b> , 119, 519-26	2.3	34
19	Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. <i>Gut</i> , <b>2007</b> , 56, 1232-9	19.2	715
18	Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. <i>Therapeutic Drug Monitoring</i> , <b>2007</b> , 29, 1-5	3.2	40
17	Rifaximin-EIR in mild to moderate active Crohn's disease (GRACE 02 study). <i>Inflammatory Bowel Diseases</i> , <b>2007</b> , 13, 668	4.5	
16	Mutation analysis of the MYH gene in unrelated Czech APC mutation-negative polyposis patients. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 1617-21	7.5	9
15	What is the origin of ulcerative colitis? Still more questions than answers. <i>Postgraduate Medical Journal</i> , <b>2006</b> , 82, 620-5	2	20
14	6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. <i>Digestion</i> , <b>2006</b> , 73, 25-31	3.6	58
13	Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. <i>Gastroenterology</i> , <b>2006</b> , 130, 323-33; quiz 591	13.3	1305
12	European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. <i>Gut</i> , <b>2006</b> , 55 Suppl 1, i36-58	19.2	308
11	Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease. <i>Gut</i> , <b>2006</b> , 55, 1525-6	19.2	45
10	Deficiency of Adenomatous Polyposis Coli protein in sporadic colorectal adenomas and its associations with clinical phenotype and histology. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 3901-5	5.6	2

9	A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 303-9	13.4	78
8	A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 21, 133-40	6.1	37
7	Massive, Life-Threatening Bleeding in Crohn's Disease. <i>Acta Chirurgica Belgica</i> , <b>2005</b> , 105, 168-174	0.9	29
6	Maintenance of Remission over 1 Year in Patients with Active Crohn's Disease Treated with Adalimumab. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, S311	0.7	4
5	Remission and Clinical Response Induced and Maintained in Patients with Active Crohn's Disease Treated for 1-Year Open-Label with Adalimumab. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, S316-S317	0.7	2
4	Maintaining remission of ulcerative colitis with the probiotic <i>Escherichia coli</i> Nissle 1917 is as effective as with standard mesalazine. <i>Gut</i> , <b>2004</b> , 53, 1617-23	19.2	812
3	A randomized, double-blind, placebo-controlled trial of the human anti-TNF- $\alpha$ monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. <i>Gastroenterology</i> , <b>2004</b> , 127, 332	13.3	37
2	Absence of nocturnal acid breakthrough in <i>Helicobacter pylori</i> -positive subjects treated with twice-daily omeprazole. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 445-50	2.2	7
1	Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , <b>2001</b> , 7, 237-42	4.5	50